WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

In Ireland, WuXi Biologics has sold a new vaccines plant to Merck & Co. for €500 million ($521 million). The New Jersey ...

The acquisition from Wuxi Biologics, the embattled CDMO named in the BIOSECURE Act, marks another expansion of Merck’s ...

US pharmaceutical group adds eighth Irish manufacturing site to its network as it promises to deliver 1,000 jobs this year ...

WuXi Biologics plans to sell its vaccine facility in Dundalk, Ireland to Merck & Co. for approximately $500 million. This ...

WuXi upgraded its WuXiBody platform in bispecific antibody discovery to address the growing global demand for these complex ...

China's WuXi Biologics has confirmed it will sell its vaccine facility in Ireland to US drugmaker Merck & Co for about €500 ...

The pharmaceutical firm MSD is buying out the WuXi Vaccines manufacturing plant in Dundalk, in a €500m deal. The American ...

Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...

WUXI Biologics Cayman will sell a vaccine facility in Ireland to Merck for about US$500 million as the Chinese company seeks ...